Purchase this article with an account.
Kazuyoshi Kitamura, Tatsuya Chiba, Fumihiko Mabuchi, Satoshi Kogure, Fumiko Kashiwagi, Shigeo Tsukahara, Kenji Kashiwagi; Comparison of effect of oral lomerizine and methylcobalamin on visual field defect in primary open angle glaucoma and normal tension glaucoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):563.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare effect of orally administered lomerizine and methylcobalamin on visual field defect in primary open angle glaucoma (POAG) and normal tension glaucoma (NTG).
Adult patients with POAG or NTG whose intraocular pressure (IOP) was controlled under 18 mmHg were randomly prescribed 10 mg of lomerizine or 1500 μg of methylcobalamin per day. Static visual field testing, fundus examination and IOP, blood pressure (BP), and pulse rate (PR) measurements were carried out every four months up to three years. Change in mean deviation (MD) slope in eyes showing much faster deterioration was compared between lomerizine group and methylcobaramin group as a primary outcome measure.
Of 120 enrolled subjects, 101 subjects (49 males and 52 females; 63.11±1.4 years) satisfied the study protocol. Only one patient quit the study due to nausea in the lomerizine group. There were no significant difference in the lomerizine group and the methylcobaramin group regards as the entry characteristics. MD slopes of the lomerizine group and the methylcobaramin group were -0.41 ± 0.3 and -1.0 ± 0.9 dB, respectively (P<0.001). Oral lomerizine did not effect on BP and PR, and no significant difference in IOP and BP, and PR were observed between the two groups during the follow up period.
Lomerizine significantly reduced deterioration of glaucomatous visual field loss than methylcobaramin.
This PDF is available to Subscribers Only